- Home
- BIAF vs BCDA Comparison
BIAF vs BCDA Comparison
Compare BIAF & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- BCDA
- Stock Information
- Founded
- BIAF 2014
- BCDA N/A
- Country
- BIAF United States
- BCDA United States
- Employees
- BIAF N/A
- BCDA N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- BCDA Health Care
- Exchange
- BIAF Nasdaq
- BCDA Nasdaq
- Market Cap
- BIAF 12.2M
- BCDA 11.0M
- IPO Year
- BIAF 2022
- BCDA N/A
- Fundamental
- Price
- BIAF $0.30
- BCDA $2.15
- Analyst Decision
- BIAF Hold
- BCDA Strong Buy
- Analyst Count
- BIAF 1
- BCDA 1
- Target Price
- BIAF N/A
- BCDA $25.00
- AVG Volume (30 Days)
- BIAF 11.2M
- BCDA 52.3K
- Earning Date
- BIAF 08-13-2025
- BCDA 08-12-2025
- Dividend Yield
- BIAF N/A
- BCDA N/A
- EPS Growth
- BIAF N/A
- BCDA N/A
- EPS
- BIAF N/A
- BCDA N/A
- Revenue
- BIAF $8,809,228.00
- BCDA $3,000.00
- Revenue This Year
- BIAF N/A
- BCDA N/A
- Revenue Next Year
- BIAF $20.00
- BCDA N/A
- P/E Ratio
- BIAF N/A
- BCDA N/A
- Revenue Growth
- BIAF 78.40
- BCDA N/A
- 52 Week Low
- BIAF $0.16
- BCDA $1.63
- 52 Week High
- BIAF $2.99
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- BIAF 50.96
- BCDA 51.13
- Support Level
- BIAF $0.22
- BCDA $1.98
- Resistance Level
- BIAF $0.46
- BCDA $2.45
- Average True Range (ATR)
- BIAF 0.04
- BCDA 0.17
- MACD
- BIAF 0.01
- BCDA 0.01
- Stochastic Oscillator
- BIAF 30.51
- BCDA 53.19
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).